MEF2 Transcription Factors

Activating transcription factors of the MADS family which bind a specific sequence element (MEF2 element) in many muscle-specific genes and are involved in skeletal and cardiac myogenesis, neuronal differentiation and survival/apoptosis.

Also Known As:

MEF2 Proteins; MEF2A Protein; MEF2A Transcription Factor; MEF2B Protein; MEF2B Transcription Factor; MEF2C Protein; MEF2C Transcription Factor; MEF2D Protein; MEF2D Transcription Factor; Muscle Enhancer Factor-2; Muscle Enhancer Factor-2A; Muscle Enhancer Factor-2B; Muscle Enhancer Factor-2C; Muscle Enhancer Factor-2D; Muscle-Specific Enhancer Factor-2; Muscle-Specific Enhancer Factor-2A; Muscle-Specific Enhancer Factor-2B; Muscle-Specific Enhancer Factor-2C; Muscle-Specific Enhancer Factor-2D; Myocyte Enhancer Factor 2; Myocyte Enhancer Factor 2A; Myocyte Enhancer Factor 2B; Myocyte Enhancer Factor 2C; Myocyte Enhancer Factor 2D; Myocyte-Specific Enhancer Factor 2; Myocyte-Specific Enhancer Factor 2A; Myocyte-Specific Enhancer Factor 2B; Myocyte-Specific Enhancer Factor 2C; Myocyte-Specific Enhancer Factor 2D; Myocyte-Specific Enhancer-Binding Factor 2; Myocyte-Specific Enhancer-Binding Factor 2A; Myocyte-Specific Enhancer-Binding Factor 2B; Myocyte-Specific Enhancer-Binding Factor 2C; Myocyte-Specific Enhancer-Binding Factor 2D; Serum Response Factor-Like Protein 1; Serum Response Factor-Like Protein 2; Enhancer Factor-2, Muscle; Enhancer Factor-2, Muscle-Specific; Enhancer Factor-2A, Muscle; Enhancer Factor-2A, Muscle-Specific; Enhancer Factor-2B, Muscle; Enhancer Factor-2B, Muscle-Specific; Enhancer Factor-2C, Muscle; Enhancer Factor-2C, Muscle-Specific; Enhancer Factor-2D, Muscle; Enhancer Factor-2D, Muscle-Specific; Muscle Enhancer Factor 2; Muscle Enhancer Factor 2A; Muscle Enhancer Factor 2B; Muscle Enhancer Factor 2C; Muscle Enhancer Factor 2D; Muscle Specific Enhancer Factor 2; Muscle Specific Enhancer Factor 2A; Muscle Specific Enhancer Factor 2B; Muscle Specific Enhancer Factor 2C; Muscle Specific Enhancer Factor 2D; Myocyte Specific Enhancer Binding Factor 2; Myocyte Specific Enhancer Binding Factor 2A; Myocyte Specific Enhancer Binding Factor 2B; Myocyte Specific Enhancer Binding Factor 2C; Myocyte Specific Enhancer Binding Factor 2D; Myocyte Specific Enhancer Factor 2; Myocyte Specific Enhancer Factor 2A; Myocyte Specific Enhancer Factor 2B; Myocyte Specific Enhancer Factor 2C; Myocyte Specific Enhancer Factor 2D; Serum Response Factor Like Protein 1; Serum Response Factor Like Protein 2; Transcription Factor, MEF2A; Transcription Factor, MEF2B; Transcription Factor, MEF2C; Transcription Factor, MEF2D; Transcription Factors, MEF2

Networked: 195 relevant articles (4 outcomes, 17 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843

Experts

1.	Olson, Eric N: 5 articles (01/2008 - 11/2002)
2.	Wang, Jun: 3 articles (07/2022 - 01/2018)
3.	Nishimori, Shigeki: 3 articles (01/2021 - 06/2015)
4.	Swerdlow, Steven H: 3 articles (12/2020 - 10/2017)
5.	Chun, Hyung J: 3 articles (01/2019 - 01/2015)
6.	Huber, Kimberly M: 3 articles (01/2018 - 12/2012)
7.	Wilkerson, Julia R: 3 articles (01/2018 - 12/2012)
8.	Yan, Li: 3 articles (11/2017 - 08/2007)
9.	Liu, Limei: 3 articles (01/2017 - 03/2014)
10.	Qian, Cheng: 3 articles (01/2017 - 03/2014)

Related Diseases

1.	Fibrosis (Cirrhosis) 05/24/2016 - "Inhibition of myocyte-specific enhancer factor 2A improved diabetic cardiac fibrosis partially by regulating endothelial-to-mesenchymal transition." 05/24/2016 - "This study sought to identify whether inhibition of Myocyte enhancer factor 2A (MEF2A) alleviates cardiac fibrosis by partially regulating Endothelial-to-mesenchymal transition (EndMT). " 04/01/2019 - "Compared to treatment with BMSCs alone, in vitro preconditioning of BMSCs with NaHS improved left ventricular function as measured by echocardiography and electrocardiography and enhanced stem cell homing, proliferation and differentiation as manifested by higher cardiac expression of GATA-4 and myocyte enhancer factor 2. Moreover, the measurement of cardiac transforming growth factor beta 1 levels and histopathological investigation revealed mitigated fibrosis and myocardial injury scores. " 02/05/2010 - "Unlike conditional deletion of LAP2alpha in late embryonic striated muscle, its complete knockout caused systolic dysfunction in young mice, accompanied by sporadic fibrosis in old animals, as well as deregulation of major cardiac transcription factors GATA4 and myocyte enhancer factor 2c. " 11/01/2018 - "LVAD support was associated with CaMKIIδ activation, increased nuclear myocyte enhancer factor 2, sustained histone deacetylase-4 phosphorylation, increased circulating and cardiac myostatin (MSTN) and MSTN signaling mediated by SMAD2, ongoing structural protein dysregulation and sustained fibrosis and apoptosis (all P < 0.05). "
2.	Neoplasms (Cancer) 12/01/2018 - "While MEF2 transcription factors are well known to cooperate in orchestrating cell fate and adaptive responses during development and adult life, additional studies over the last decade have identified a wide spectrum of genetic alterations of MEF2 in different cancers. " 07/20/2023 - "Myocyte enhancer factor 2D (MEF2D) can participate in the process of tumor lesions by regulating the transcription of oncogenes. " 02/28/2023 - "Myocyte enhancer factor 2D (MEF2D) is involved in the progression of various malignant tumors. " 12/01/2020 - "We have overexpressed Notch signaling alone or in combination with the developmental regulator Myocyte enhancer factor 2 (Mef2) using wing-specific and eye-specific drivers, quantified the size of LDs in the fat body of the different tumor bearing larvae, and estimated the expression of genes associated with lipolysis and lipogenesis. " 01/24/2020 - "Mechanistically, SOX2 upregulation is attributed to the binding of the acetylated myocyte enhancer factor 2A (MEF2A) to SOX2 promoter in tumor cells. "
3.	Insulin Resistance 01/01/2015 - "Recent evidence demonstrated that the Gly482Ser single nucleotide polymorphism (SNP) in the PGC-1α gene affects insulin sensitivity, blood lipid metabolism and binding to myocyte enhancer factor 2 (MEF2). " 08/25/2020 - "The improved muscle performance of the SDC group was based on an increase in myocyte enhancer factor 2D (MEF2D) and creatine kinase as markers of muscle differentiation as well as better insulin sensitivity, enhanced glucose uptake, and increased metabolic flexibility. " 03/31/2010 - "To investigate the effects of ethanol on the expression of AMP-activated protein kinase (AMPK), myocyte enhancer factor 2 (MEF2) and glucose transporter 4 (GLUT4), all of which are involved in the regulation of insulin sensitivity, in the myocardium, we performed three parts of experiments in vivo and in vitro. "
4.	Atrophy 01/01/2020 - "Instead, we find that skeletal muscle atrophy is characterized by diminished function of the transcriptional regulator Myocyte Enhancer Factor 2 (MEF2), a regulator of myofiber homeostasis. " 01/01/2021 - "In the context of cancer, FoxP1 knockdown blocked the cancer-induced repression of myocyte enhancer factor 2 (MEF2)-target genes critical to muscle differentiation and repair, improved muscle ultrastructure, and attenuated muscle fibre atrophy by 50% (P < 0.05). "
5.	Cardiomegaly (Heart Hypertrophy) 01/01/2022 - "On the contrary, HDAC II binds to myocyte-specific enhancer factor 2 (MEF2), inhibit the assemble ability to HAT and protect against cardiac hypertrophy. " 01/01/2004 - "Balancing contractility and energy production: the role of myocyte enhancer factor 2 (MEF2) in cardiac hypertrophy." 01/01/2011 - "In contrast, class IIa HDACs have been shown to repress cardiac hypertrophy by inhibiting cardiac-specific transcription factors such as myocyte enhancer factor 2 (MEF2), GATA4, and NFAT in the heart. " 05/01/2010 - "The calcineurin-myocyte enhancer factor 2c pathway mediates cardiac hypertrophy induced by endoplasmic reticulum stress in neonatal rat cardiomyocytes." 10/09/2009 - "Myocyte enhancer factor 2C (MEF2C) plays an important role in cardiovascular development and is a key transcription factor for cardiac hypertrophy. "

Related Drugs and Biologics

1.	Transforming Growth Factor beta (TGF-beta)
2.	Glucose (Dextrose)
3.	Creatine Kinase (Creatine Phosphokinase)
4.	sodium bisulfide (NaHS)
5.	Transcription Factors (Transcription Factor)
6.	myocardin
7.	Carrier Proteins (Binding Protein)
8.	Catenins
9.	protein kinase D
10.	Neurotrophin 3

Related Therapies and Procedures

1.	Heart-Assist Devices